18:32:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-06-28 Extra Bolagsstämma 2024
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021


ListaSpotlight DK
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2022-10-10 16:24:34

CS MEDICA A/S ("CS MEDICA" or the" Company") announces that the Company will close the year with a revenue of 10,6M DKK delivered with well-known partners within the industry. Alliance Healthcare Romania, part of the Alliance Healthcare, one of the largest wholesalers in Europe, will market the Cannasen® brand and all SKUs. Whereas, the Spanish Aldo-Union will bring the unique formulas and products in their own brand to patients in Spain.

Lone Henriksen, CEO CS MEDICA, comments  

"We are happy to announce that CS MEDICA is closing the year with 10,6M DKK in revenue, and we are proud of the strong partnerships we have developed in the last months. We have moved from being an R&D to a commercialized company, now listed in most pharmacies in DK, on Amazon, and we have signed with distributors in Israel, Hong Kong, Slovenia, Croatia, and Serbia to market our Cannasen® brand. The latest distribution partner we have teamed up with is Alliance Healthcare Romania, part of the Alliance Healthcare, one of the largest wholesalers in Europe, supplying more than 115,000 pharmacies, doctors, and health centers in 13 countries. This order includes our full Cannasen® portfolio incl. the new Wound Gel."

Lone Henriksen, CEO CS MEDICA, continues

"We also see the interest in white labels grows rapidly, helping us penetrate the markets with our unique CBD technology. For example, we have extended the portfolio with Alsitan in Germany. For our latest partnership, we have signed a significant agreement with the well-known Spanish company Aldo-Union, another important player in the industry which wants to utilize our first mover formulas with their brand in several countries".   

The revenue growth of 331% versus last year delivers a solid base for the further pipeline. The remaining approx. 1,4M DKK to reach the target of 12M DKK is covered by two contracts not yet signed, as the final registration details are still pending. These will be closed in the coming quarter.

Lone Henriksen, CEO CS MEDICA, comments

"The process for teaming up with new partners takes 6+ months, depending on the region and the legislation window. And with the product lead time increasing due to resource challenges, we acknowledge we must build a larger pipeline on both sales and stock. Hence, we found a strong partner, one of the four major wholesalers in the Dutch market, with an understanding of the pharmaceutical marketplace. We see this as an opportunity to accelerate our roll-out, testing different channels and marketing initiatives. In addition, it will help us create a distribution hub closer to our productions, Amazon fulfillment, and other partners as we're looking into minimizing freight and shipping miles. We believe this can open the doors for the markets faster in Europe."

As a biotech company offering unique CBD technology, white labels, and finished branded OTC products with high efficacy, CS MEDICA looks forward to moving into a new fiscal year with a more robust base and core market learnings to reach new businesses and goals going forward.

CS MEDICA will invite to investor call when year-end details are in place and communicated. Information will be shared at a later stage.

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-10-2022 16:24 CET.